泼尼松治疗的风湿性多肌痛或巨细胞动脉炎患者中肾上腺功能不全的患病率与临床处理
该研究纳入47例接受泼尼松≥5.4个月、当前剂量2.5-10 mg/天的风湿性多肌痛(PMR)或巨细胞动脉炎(GCA)患者,用促肾上腺皮质激素刺激试验评估肾上腺功能。15%存在肾上腺功能不全,近3个月平均泼尼松剂量和基础皮质醇是最好预测指标,多数肾上腺功能不全患者可安全停用泼尼松。
要点
- PMR/GCA泼尼松治疗患者中肾上腺功能不全患病率为15%。
- 近3个月平均泼尼松剂量和基础皮质醇是肾上腺功能的最佳预测指标。
- 多数肾上腺功能不全患者可停用泼尼松,但部分需长期氢化可的松替代。
核心结论
- 泼尼松治疗的PMR/GCA患者中糖皮质激素诱导的肾上腺功能不全患病率为15%。
研究设计与样本
- 纳入47例PMR(37例)、GCA(1例)或两者兼有(9例)的患者,泼尼松治疗≥5.4个月,当前剂量2.5-10 mg/天。
- 停用泼尼松48小时后行促肾上腺皮质激素(Synacthen®)刺激试验评估肾上腺功能,并提供2年临床随访数据。
主要发现
- 7例(15%)存在肾上腺功能不全,其中单纯PMR患者4/37例(11%),GCA患者3/10例(30%)。
- 促肾上腺皮质激素刺激后的血浆皮质醇与当前泼尼松剂量、检测前近3个月和6个月的平均日剂量及基础血浆皮质醇显著相关,但与总剂量或治疗持续时间无关。
- 肾上腺功能不全可见于所有当前泼尼松剂量(2.5-10 mg/天)。
- 5例(71%)肾上腺功能不全患者可停用泼尼松,其中2例恢复糖皮质激素功能,3例2年后仍需氢化可的松替代。
- 2例患者共发生4次因肾上腺危象症状的急性住院。
关键数值与推荐
- 肾上腺功能不全定义为促肾上腺皮质激素刺激试验异常(原文未给出具体阈值)。
- 近3个月平均泼尼松剂量和基础血浆皮质醇是肾上腺功能的最佳且最简单的预测指标。
临床怎么用
- 对长期泼尼松治疗的PMR/GCA患者应警惕肾上腺功能不全,尤其是当前剂量较低时仍可能发生。
- 可利用近3个月平均泼尼松剂量和基础血浆皮质醇评估肾上腺功能,指导泼尼松减停。
- 确诊肾上腺功能不全的患者在适当治疗后多数可停用泼尼松,但需监测是否需要氢化可的松替代。
局限性
- 样本量较小(47例),GCA患者仅10例。
- 原文未报告试验的具体诊断阈值。
- 随访数据有限,长期结局需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Glucocorticoid treatment is fundamental in polymyalgia rheumatica (PMR) and giant cell arteritis (GCA), but carries a risk of glucocorticoid-induced adrenal insufficiency. Adrenal insufficiency can cause reluctance to stop glucocorticoid treatment after disease remission as symptoms can resemble PMR/GCA flare. We aimed to determine the prevalence of adrenal insufficiency in prednisolone-treated patients with PMR/GCA. METHODS: We included 47 patients with PMR (n = 37), GCA (n = 1) or both (n = 9), treated with prednisolone for ≥5.4 months, current dose 2.5-10 mg/day. Adrenal function was evaluated using a corticotropin (Synacthen®) stimulation test following 48 h prednisolone pause. Two years' clinical follow-up data are provided. RESULTS: Seven patients (15%) had adrenal insufficiency, 4 (11%) of the 37 patients with PMR alone, and 3 (30%) of the 10 patients with GCA. Corticotropin-stimulated P-cortisol was significantly associated with current prednisolone dose, mean daily dose the last 3 and 6 months before testing, and basal P-cortisol, but not with total dose or treatment duration. Adrenal insufficiency occurred with all current prednisolone doses (2.5-10 mg/day). Five (71%) of the glucocorticoid-insufficient patients could discontinue prednisolone treatment; two of them recovered glucocorticoid function, whereas three still needed hydrocortisone replacement 2 years later. Two patients experienced in total four acute hospital admissions with symptoms of adrenal crises. CONCLUSION: Glucocorticoid-induced adrenal insufficiency occurred in 15% of patients with PMR/GCA. Mean prednisolone dose the last 3 months and basal P-cortisol were the best and simplest predictors of adrenal function. Most of the glucocorticoid-insufficient patients could discontinue prednisolone with appropriate treatment for adrenal insufficiency.
引用
- Borresen SW, Thorgrimsen TB, Jensen B, et al. Adrenal insufficiency in prednisolone-treated patients with polymyalgia rheumatica or giant cell arteritis-prevalence and clinical approach. Rheumatology (Oxford). 2020. PMID: 32031663. doi:10.1093/rheumatology/keaa011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。